Paper22089340
Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond.
Mandema JW and 4 others. Clin Pharmacol Ther, 2011. Cited by 95 papers, by iCite.
Cite this record
ConductScience Library. Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Papers, record 22089340. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22089340
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Anticoagulants | Major topic |
| Antirheumatic Agents | Major topic |
| Arthritis, Rheumatoid | Major topic |
| Orthopedic Procedures | Major topic |
| Venous Thromboembolism | Major topic |
| Humans |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment on | 22048227 | A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. | https://conductscience.org/library/papers/22048227 | PubMed |
| Comment on | 22048231 | Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis. | https://conductscience.org/library/papers/22048231 | PubMed |
Cited by56
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 95 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42438069 | Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/42438069 | PubMed |
| 42085320 | MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/42085320 | PubMed |
| 41754991 | Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41754991 | PubMed |
| 41347637 | Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/41347637 | PubMed |
| 41338640 | Dose-effect relationship of intravenous tranexamic acid on perioperative haemoglobin drop in total hip arthroplasty (PRADO study): study protocol for a randomised, double-blind, placebo-controlled, dose-response study. | BMJ Open | 2025 | https://conductscience.org/library/papers/41338640 | PubMed |
| 41023527 | Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach. | Dermatol Ther (Heidelb) | 2025 | https://conductscience.org/library/papers/41023527 | PubMed |
| 40326484 | Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis. | J Clin Pharmacol | 2025 | https://conductscience.org/library/papers/40326484 | PubMed |
| 40160292 | Pharmacodynamic Modeling of Cinacalcet in Secondary Hyperparathyroidism: Efficacy and Influencing Factors Analysis. | J Endocr Soc | 2025 | https://conductscience.org/library/papers/40160292 | PubMed |
| 39862179 | Quantitative evaluation of multiple treatment regimens for treatment-resistant depression. | Int J Neuropsychopharmacol | 2025 | https://conductscience.org/library/papers/39862179 | PubMed |
| 39379875 | Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies. | BMC Neurol | 2024 | https://conductscience.org/library/papers/39379875 | PubMed |
| 39245866 | Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-Analysis. | Clin Pharmacol Ther | 2025 | https://conductscience.org/library/papers/39245866 | PubMed |
| 38522000 | Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice. | CPT Pharmacometrics Syst Pharmacol | 2024 | https://conductscience.org/library/papers/38522000 | PubMed |
| 38308282 | Accelerating drug development for amyotrophic lateral sclerosis: construction and application of a disease course model using historical placebo group data. | Orphanet J Rare Dis | 2024 | https://conductscience.org/library/papers/38308282 | PubMed |
| 38183573 | Model-Based Meta-Analysis Supporting the Combination of Acetaminophen and Topical Diclofenac in Acute Pain: A Therapy for Mild-to-Moderate Osteoarthritis Pain? | Pain Ther | 2024 | https://conductscience.org/library/papers/38183573 | PubMed |
| 38183572 | Model-Based Assessment of the Liver Safety Profile of Acetaminophen to Support its Combination Use with Topical Diclofenac in Mild-to-Moderate Osteoarthritis Pain. | Pain Ther | 2024 | https://conductscience.org/library/papers/38183572 | PubMed |
| 37702936 | In Silico Clinical Trials: Is It Possible? | Methods Mol Biol | 2024 | https://conductscience.org/library/papers/37702936 | PubMed |
| 37507595 | LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data. | Eur J Clin Pharmacol | 2023 | https://conductscience.org/library/papers/37507595 | PubMed |
| 37345104 | Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345104 | PubMed |
| 37304299 | Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. | Front Immunol | 2023 | https://conductscience.org/library/papers/37304299 | PubMed |
| 36947282 | Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials. | J Pharmacokinet Pharmacodyn | 2023 | https://conductscience.org/library/papers/36947282 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22089340
GET https://conductscience.org/api/papers/v1/22089340/cited_by?page=2